EMA Authorised: Vipidia (alogliptin) — Takeda Pharma A/S

View source ↗

Summary

The EMA authorises Vipidia (alogliptin) for type 2 diabetes mellitus, with Takeda Pharma A/S as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vipidia (alogliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Takeda Pharma A/S. Decision date: 25/05/2023